Protagonist Therapeutics (NASDAQ:PTGX) Director Harold Selick Sells 24,000 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Harold Selick sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the sale, the director directly owned 60,845 shares of the company’s stock, valued at approximately $6,388,725. This represents a 28.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Protagonist Therapeutics Stock Down 3.1%

Shares of PTGX stock opened at $98.97 on Friday. The firm has a market cap of $6.32 billion, a price-to-earnings ratio of -48.28 and a beta of 2.23. Protagonist Therapeutics, Inc. has a 12 month low of $39.60 and a 12 month high of $105.69. The stock has a 50-day moving average price of $88.99 and a 200 day moving average price of $82.50.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: One‑year Phase 3 clinical data for ICOTYDE (icotrokinra) were presented at the 2026 AAD meeting showing durable skin clearance and a favorable safety profile for this once‑daily oral IL‑23 receptor targeted peptide, reinforcing ICOTYDE’s differentiated positioning in moderate‑to‑severe plaque psoriasis. AAD Presentation
• Positive Sentiment: An analyst price target was raised (reported as an 11.65% increase to $114.50), which signals at least one analyst firm sees more upside following recent data/updates. Analyst optimism can support longer‑term upside. Price Target Increase
• Neutral Sentiment: Industry/strategy commentary (ClearBridge / ClearBridge Small Cap Growth Strategy mention) discusses the company’s pipeline and potential; useful context but not an immediate catalyst. Industry Note
• Negative Sentiment: Multiple insiders (including the CFO Asif Ali, a board director Harold Selick, and insider Arturo Molina) sold shares on March 26 — approximately 63,765 shares disclosed across filings, representing several million dollars of stock sold. Large, clustered insider sales are being read negatively by the market and likely contributed to near‑term selling pressure. Insider SEC Filing

Analyst Upgrades and Downgrades

PTGX has been the subject of a number of analyst reports. TD Cowen lifted their target price on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. JPMorgan Chase & Co. increased their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Weiss Ratings lowered Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Barclays lifted their price objective on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.31.

Institutional Investors Weigh In On Protagonist Therapeutics

Several hedge funds have recently bought and sold shares of PTGX. Farther Finance Advisors LLC boosted its position in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the 4th quarter valued at $27,000. Salomon & Ludwin LLC bought a new stake in shares of Protagonist Therapeutics in the 3rd quarter valued at $29,000. EverSource Wealth Advisors LLC raised its stake in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after buying an additional 314 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new stake in Protagonist Therapeutics during the 3rd quarter worth $62,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.